What is Letybo and who makes it?

Letybo is a botulinum toxin product launched by Hugel, a South Korean toxin manufacturer, now available in India. Hugel is positioning Letybo as a competitive alternative to established toxin brands in one of the world's fastest-growing aesthetics markets.

How fast is India's aesthetics market growing?

India's aesthetics market is growing 15–20% annually, driven by rising disposable income, younger demographics, and increasing acceptance of cosmetic procedures. This makes it one of the most attractive expansion targets for global aesthetics companies.

What market share is Hugel targeting in India?

Hugel is targeting 9% market share in India by 2026, which would represent roughly 1 in 11 toxin units sold in the country. This is an aggressive but achievable goal if Hugel can secure strong physician relationships and navigate India's regulatory environment.

Why does Hugel's India expansion matter for US med spas?

Hugel's international expansion funds R&D and manufacturing scale, which eventually lowers per-unit toxin costs and increases competitive pricing pressure in the US market. It also signals Hugel's ambition to become a truly global player, not just a regional alternative.

Is Hugel new to international markets?

No—the India launch follows Hugel's US expansion, reflecting a deliberate strategy to build global scale outside mature North American and European markets. This phased international approach positions Hugel as an increasingly serious global competitor.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Market

Hugel Launches Letybo in India, Targets 9% Market Share by 2026

South Korean toxin maker enters India's fast-growing aesthetics market with aggressive growth targets and direct commercial infrastructure.

By Evan at Inside MedSpa · Jul 23, 2026

Hugel has officially launched Letybo in India and is targeting 9% market share by 2026, signaling a major push into Asia's second-largest aesthetics market. The India entry follows Hugel's US expansion and reflects a deliberate strategy to build global scale outside the mature North American and European markets.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/hugel-letybo-india-launch-market-expansion/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

Hugel Launches Letybo in India, Targets 9% Market Share by 2026

Share

Discussion

Leave a comment

By the time it's news, it's too late.